Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Christopher Laganke (NPI 1811931546)

Field	Value
Entity Type	Individual
Organization	Christopher Laganke
Address	1809 Kress Street
City	Cullman
State	AL
ZIP	35058
Taxonomy	Neurology Physician
NPI Enumerated	June 15, 2006

Payer Source	Total Paid
Medicare	$4.4M
Medicaid	$0

Key Findings

This provider’s Medicare business is heavily dominated by high-cost infused biologic and immunotherapy drugs: J2323, J2350, and J1568 together account for 93.4% of the provider’s total Medicare revenue and individually generate $2.3M, $1.2M, and $617.4K respectively. The scale of these code-level revenues relative to the $4.4M total Medicare revenue shows that drug administration—rather than routine office evaluation and management—is the core revenue driver.

Volume counts and code mix point to an infusion-focused neurology practice: the record shows 130.2K claims for J2323, 27K claims for J2350, and 18.7K claims for J1568, consistent with ongoing in-office administration of natalizumab, ocrelizumab, and IV immune globulin therapies for neurologic conditions. High use of infusion administration codes such as 96365 (825 claims, $36.3K revenue) and multiple infusion add-on/continuation codes further supports that the operation is delivering frequent IV treatments rather than only office-based consults.

Revenue concentration is extreme: the top three Medicare codes alone account for 93.4% of Medicare revenue, indicating elevated dependency on a small set of infused specialty drugs. This concentration suggests financial sensitivity to payer policy or utilization changes affecting those specific agents and highlights that any analysis of the provider’s revenue or risk should prioritize those drugs and associated infusion services.

Competitive standing varies by code: the provider ranks #1 of 40 nationally for J2323 (100th percentile) and is described as an "extreme outlier," indicating an unusually large national footprint for natalizumab administration. For J1568 the provider ranks #9 of 381 (98th percentile) and is "notably above typical national volume," showing similarly strong standing for IVIG, while J2350 sits at #11 of 105 (90th percentile) with a label of "typical, unremarkable volume," indicating solid but less exceptional positioning on ocrelizumab.

Clinical revenue mix shows limited reliance on traditional office E/M: 99214 contributes $55.6K (1.3% of Medicare revenue) with 762 claims, which is meaningful from a visit-count perspective but small relative to infusion drug revenue. This pattern suggests the practice bills standard evaluation/management visits but that those visits are not the principal revenue source compared with infused medications.

Payer mix is effectively single-payer Medicare for billed activity: lifetime Medicare revenue is $4.4M while Medicaid shows none on file, so the provider’s reported public-payer activity is concentrated entirely with Medicare. Analysts should treat this profile as Medicare-dominant when benchmarking reimbursement, utilization, or risk exposure, and should not expect Medicaid encounter data to inform in-state payer comparisons.

Operational implications for payers include a need to focus utilization review and contract considerations on high-cost biologics and infusion workflows given the dominance of J2323, J2350, and J1568 in revenue. The presence of high national ranks—especially the extreme outlier status for J2323—means peer benchmarking and medical necessity review should be tailored to infusion frequency, dosing units, and documented indications for natalizumab and similar agents.

Tenure and experience are established: the provider’s NPI was enumerated on 2006-06-15 (~20 years ago), indicating long-standing enrollment in Medicare. That longevity, combined with unusually high infusion volumes for specific neurology therapeutics, suggests an established clinical program centered on specialty infusion services rather than a new or small-scale practice model.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2323	Injection, natalizumab, 1 mg	130,200	$20	$2.3M
J2350	Injection, ocrelizumab, 1 mg	27,000	$40	$1.2M
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	18,710	$30	$617.4K
J0585	Injection, onabotulinumtoxina, 1 unit	25,880	$1	$103.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	760	$70	$55.6K
J0586	Injection, abobotulinumtoxina, 5 units	8,220	$10	$49.3K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	830	$40	$36.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	170	$80	$14K
96366	The provider administers an intravenous infusion or infusions of a medication for an additional hour or subsequent hours after the first hour to prevent, treat, or diagnose a condition or disease.	650	$20	$9.7K
64615	The provider bilaterally administers a chemical compound to the muscles innervated by the trigeminal, facial, cervical spinal, and accessory nerves. The goal of this procedure is to paralyze the…	100	$90	$8.8K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Christopher Laganke — 4 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2323	1	10	130,200	$20	$2.4M
J2350	1	10	27,000	$40	$1.2M
J1568	3	30	5,180	$30	$316.2K
J0585	3	40	9,210	$1	$53.5K
J0586	2	10	8,220	$10	$51.2K
96413	71	150	150	$90	$20.2K
99214	351	7,330	120	$80	$16.8K
96365	3	170	130	$40	$7.5K
64616	12	10	40	$120	$7.3K
64615	5	20	60	$100	$6.2K

Showing 1–10 of 21

Related Providers

Other providers that share a Tax Identification Number (TIN) with Christopher Laganke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Central Neurology Associates, PC	AL	Neurology Physician	$0	$7.4M
Jonathan Davis	AL	Diagnostic Radiology Physician	$530.7K	$0
Heritage Diagnostic Center, LLC	AL	Magnetic Resonance Imaging (MRI) Clinic/Center	$166.1K	$233.2K
Angus Baird	AL	Diagnostic Radiology Physician	$158.2K	$0
Pamela Quinn	AL	Neurology Physician	$129.2K	$0
Joel Raborn	AL	Diagnostic Radiology Physician	$127.8K	$0
Joseph Eason	AL	Vascular & Interventional Radiology Physician	$113.6K	$0
Austin Dennis	AL	Diagnostic Radiology Physician	$112.1K	$0
Scott Thompson	AL	Diagnostic Radiology Physician	$104.3K	$0
Julian Druhan	AL	Diagnostic Radiology Physician	$98K	$0

Nearby Providers

Other providers in the same ZIP code as Christopher Laganke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Cullman Regional Medical Center, Inc	AL	General Acute Care Hospital	$0	$7.5M
Internal Medicine And Pediatrics Of Cullman	AL	Specialist	$0	$7M
Henry Robson	AL	Oral and Maxillofacial Surgery (Dentist)	$5.3K	$3.5M
Island Medical Alabama LLC	AL	Emergency Medicine Physician	$0	$3.1M
Cullman Primary Care, PC	AL	Family Medicine Physician	$0	$1.7M
Willow Tree Pediatrics PC	AL	Pediatrics Physician	$0	$1.4M
Cullman Primary Care, PC	AL	Family Medicine Physician	$0	$1.1M
Crmc Medical Group LLC	AL	Multi-Specialty Clinic/Center	$0	$972.8K
Crmc Medical Group LLC	AL	Urgent Care Clinic/Center	$0	$968.5K
Vincent Karolewics	AL	Radiation Oncology Physician	$602.3K	$0

Christopher Laganke — Billing Profile & Reimbursement Data

Sign up for Christopher Laganke — Billing Profile & Reimbursement Data policy alerts

Christopher Laganke — Billing Profile & Reimbursement Data

Sign up for Christopher Laganke — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References